Skip to content

Ketamine research published in 2024

Page 7 of 26: studies 121 to 140 of 518, newest first. Back to the ketamine overview

Studies

Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand.

Australian & New Zealand Journal of Psychiatry October 1, 2024 Alistair Carroll, Adam Bayes, Mark Montebello et al. 10 citations

Ketamine is a restricted and regulated medication in Australia and New Zealand, which has implications when considering treatment for patients with treatment-resistant depression and a history of illicit drug use, abuse or dependence. Regulations governing prescription of ketamine for treatment-resistant depression vary between jurisdictions in Australia and New Zealand, though most restrict...

DOI: 10.1177/00048674241242315 (opens in new tab) Full text (opens in new tab) Drug dependence Regulations Ketamine therapy Mental health treatment +3

Comparison of Nebulized Ketamine to Intravenous Subdissociative Dose Ketamine for Treating Acute Painful Conditions in the Emergency Department: A Prospective, Randomized, Double-Blind, Double-Dummy Controlled Trial.

Annals of emergency medicine October 1, 2024 Tommy Nguyen, Mo Mai, Amulya Choudhary et al. 11 citations

We aimed to assess and compare the analgesic efficacy and adverse effects of intravenous subdissociative-dose ketamine to nebulized ketamine in emergency department (ED) patients with acute painful conditions. We conducted a prospective, randomized, double-blind, double-dummy clinical trial in adult patients (ages 18 and older) with a numerical rating scale pain score of ≥5. We randomized...

DOI: 10.1016/j.annemergmed.2024.03.024 (opens in new tab) Full text (opens in new tab) Pain management Ketamine therapy Emergency medicine Medical research +1

Ketamine subcutaneous continuous infusion for depressive symptoms at home: A case report beyond pain use.

Palliative & Supportive Care October 1, 2024 Carolina Simões, Miguel Julião, Patrícia Calaveiras et al. 1 citation

Ketamine has been widely used in refractory pain as an opioid adjuvant. Evidence suggests that ketamine can also have an essential role in easing depressive symptoms. Its rapid onset of action makes it a valuable choice in palliative care. We present a case of a 70-year-old man with stage IV renal carcinoma and bone metastasis. The main symptoms included neuropathic pain, depression, and a...

DOI: 10.1017/S1478951524000798 (opens in new tab) Full text (opens in new tab) Depressive symptoms Home-based palliative care Subcutaneous continuous infusion Ketamine therapy +3

Out-of-Hospital Intranasal Ketamine as an Adjunct to Fentanyl for the Treatment of Acute Traumatic Pain: A Randomized Clinical Trial.

Annals of emergency medicine October 1, 2024 Jason T McMullan, Christopher A Droege, Kathleen M Chard et al. 5 citations

To evaluate if out-of-hospital administration of fentanyl and intranasal ketamine, compared to fentanyl alone, improves early pain control after injury. We conducted an out-of-hospital randomized, placebo-controlled, blinded, parallel group clinical trial from October 2017 to December 2021. Participants were male, aged 18 to 65 years, receiving fentanyl to treat acute traumatic pain prior to...

Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model.

Neuropharmacology October 1, 2024 Carolyn J Stopera, Mitchell J Bartlett, Chenxi Liu et al. 9 citations

Sub-anesthetic ketamine treatment has been shown to be an effective therapy for treatment-resistant depression and chronic pain. Our group has previously shown that sub-anesthetic ketamine produces acute anti-parkinsonian, and acute anti-dyskinetic effects in preclinical models of Parkinson's disease (PD). Ketamine is a multifunctional drug and exerts effects through blockade of...

DOI: 10.1016/j.neuropharm.2024.110047 (opens in new tab) Full text (opens in new tab) 6-hydroxydopamine Levodopa-induced dyskinesia Microdialysis Naloxone +6

Ketamine induced synaptic plasticity operates independently of long-term potentiation.

Neuropsychopharmacology October 1, 2024 Michelle K Piazza, Ege T Kavalali, Lisa M Monteggia 21 citations

Synaptic plasticity occurs via multiple mechanisms to regulate synaptic efficacy. Homeostatic and Hebbian plasticity are two such mechanisms by which neuronal synapses can be altered. Although these two processes are mechanistically distinct, they converge on downstream regulation of AMPA receptor activity to modify glutamatergic neurotransmission. However, much remains to be explored regarding...

Ketamine reduces the neural distinction between self- and other-produced affective touch: a randomized double-blind placebo-controlled study.

Neuropsychopharmacology October 1, 2024 Reinoud Kaldewaij, Paula C Salamone, Adam Enmalm et al. 19 citations

A coherent sense of self is crucial for social functioning and mental health. The N-methyl-D-aspartate antagonist ketamine induces short-term dissociative experiences and has therefore been used to model an altered state of self-perception. This randomized double-blind placebo-controlled cross-over study investigated the mechanisms for ketamine's effects on the bodily sense of self in the...

DOI: 10.1038/s41386-024-01906-2 (opens in new tab) Full text (opens in new tab) Self-perception Psychopharmacology Sensory-processing Consciousness

Low-dose ketamine as an adjunct to morphine: A randomized controlled trial among patients with and without current opioid use.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine October 1, 2024 Stine Fjendbo Galili, Bodil Hammer Bech, Hans Kirkegaard et al. 2 citations

Pain is a common complaint among patients presenting to the emergency department (ED), yet pain treatment is frequently suboptimal. The aim of this study was to determine the effectiveness of low-dose ketamine (LDK) as an adjunct to morphine versus morphine alone for treatment of acute pain among ED patients with and without current opioid use. Adult patients presenting with acute pain of ≥5 on...

Alfentanil versus fentanyl for emergency department rapid sequence induction with ketamine: A-FAKT, a pilot randomized trial.

The American Journal of Emergency Medicine October 1, 2024 Yichen Zhang, Matthew Miller, Alexander Buttfield et al. 2 citations

Fentanyl is often administered during rapid sequence induction of anesthesia (RSI) in the emergency department (ED) to ameliorate the hypertensive response that may occur. Due to its more rapid onset, the use of alfentanil may be more consistent with both the onset time of the sedative and the commencement of laryngoscopy. As such, we compared the effect of alfentanil and fentanyl on...

Ketamine-dependent patients with persistent psychosis have higher neurofilament light chain levels than patients with schizophrenia.

Asian Journal of Psychiatry October 1, 2024 An-Nie Chung, Ming-Chyi Huang, Tung-Hsia Liu et al. 5 citations

Ketamine can induce persisting psychosis in a subset of individuals who use it chronically and heavily. Previously, we found that the psychopathology and cognitive impairments in patients with ketamine dependence (KD) exhibiting persistent psychosis (KPP) bear resemblances with schizophrenia, albeit with less severity in those with no persistent psychosis (KNP). Furthermore, we also showed that...

DOI: 10.1016/j.ajp.2024.104167 (opens in new tab) Full text (opens in new tab) Ketamine dependence Ketamine psychosis Neurofilament light chain Persistent psychosis +4

Neural correlates of treatment response to ketamine for treatment-resistant depression: A systematic review of MRI-based studies.

Psychiatry Research October 1, 2024 Je-Yeon Yun, Yong‐Ku Kim 11 citations

Treatment-resistant depression (TRD) is defined as patients diagnosed with depression having a history of failure with different antidepressants with an adequate dosage and treatment duration. The NMDA receptor antagonist ketamine rapidly reduces depressive symptoms in TRD. We examined neural correlates of treatment response to ketamine in TRD through a systematic review of brain magnetic...

IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.

Psychiatry Research October 1, 2024 Gilmar Gutierrez, Jennifer Swainson, Nisha Ravindran et al. 17 citations

Intravenous (IV) ketamine and intranasal (IN) esketamine are novel therapies to manage treatment resistant depression within major depressive disorder (MDD-TRD). This is a multi-site observational study aiming to assess the real-world effectiveness and tolerability of these novel therapies in the management of MDD-TRD. 53 patients were referred to receive IV ketamine (n = 26, 69.23 % female,...

Sex difference alters the behavioral and cognitive performance in a rat model of schizophrenia induced by sub-chronic ketamine.

Journal of Psychiatric Research October 1, 2024 Mohammad-Ali Samizadeh, Seyedeh-Tabassom Abdollahi-Keyvani, Hamed Fallah et al. 21 citations

Schizophrenia is a complex neuropsychiatric disorder with positive, negative, and cognitive symptoms. In rats, sub-chronic administration of ketamine is used for the induction of schizophrenia model. Increased locomotor activity is one of the most important features of psychotic-like symptoms in rodents. On the other hand, risperidone is a potent antipsychotic medication that is approved for...

Fast-acting antidepressant-like effects of ketamine in aged male rats.

Pharmacological Reports October 1, 2024 Elena Hernández-Hernández, Sandra Ledesma-Corvi, Jordi Jornet-Plaza et al. 8 citations

The aging process causes anatomical and physiological changes that predispose to the development of late-life depression while reduces the efficacy of classical antidepressants. Novel fast-acting antidepressants such as ketamine might be good candidates to be explored in the context of aging, especially given the lack of previous research on its efficacy for this age period. Thus, the aim of...

DOI: 10.1007/s43440-024-00636-y (opens in new tab) Full text (opens in new tab) Aging Bdnf Fast-acting antidepressant Ketamine therapy +4

Ketamine alleviates PTSD-like effect and improves hippocampal synaptic plasticity via regulation of GSK-3β/GR signaling of rats.

Journal of Psychiatric Research October 1, 2024 Zixun Wang, Xinyu Hu, Zhongyi Wang et al. 9 citations

Each year, 3-4% of the global population experiences post-traumatic stress disorder (PTSD), a chronic mental disorder with significant social and economic repercussions. Although it has been shown that ketamine can effectively alleviate PTSD symptoms in individuals, the specific mechanism of action underlying its anti-PTSD effects remains unclear. In this study, we investigated how a single,...

GluN2B on Adult-Born Granule Cells Modulates (R,S)-Ketamine's Rapid-Acting Effects in Mice.

The International Journal of Neuropsychopharmacology October 1, 2024 Nicholas E Bulthuis, Josephine C McGowan, Liliana R Ladner et al. 2 citations

Standard antidepressant treatments often take weeks to reach efficacy and are ineffective for many patients. (R,S)-ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be a rapid-acting antidepressant and to decrease depressive symptoms within hours of administration. While previous studies have shown the importance of the GluN2B subunit of the NMDA receptor on...

Ketamine Prevents Inflammation-Induced Reduction of Human Hippocampal Neurogenesis via Inhibiting the Production of Neurotoxic Metabolites of the Kynurenine Pathway.

The International Journal of Neuropsychopharmacology October 1, 2024 Gargi Mandal, Madeline Kirkpatrick, Silvia Alboni et al. 12 citations

Understanding the precise mechanisms of ketamine is crucial for replicating its rapid antidepressant effects without inducing psychomimetic changes. Here, we explore whether the antidepressant-like effects of ketamine enantiomers are underscored by protection against cytokine-induced reductions in hippocampal neurogenesis and activation of the neurotoxic kynurenine pathway in our...

DOI: 10.1093/ijnp/pyae041 (opens in new tab) Full text (opens in new tab) Cytokines Apoptosis Hippocampal neurogenesis Kynurenine pathway +3

Intravenous ketamine successfully treats treatment-resistant catatonia in schizophrenia: A case report.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy October 1, 2024 Atif Siddiqui 5 citations

Benzodiazepines and electroconvulsive therapy (ECT) are mainstay treatments for catatonia, a potentially life-threatening psychomotor syndrome characterized by a range of symptoms, including immobility, mutism, stupor, posturing, and sometimes even agitation. It can be a manifestation of various underlying psychiatric or medical conditions, such as schizophrenia, mood disorders, or neurological...

DOI: 10.1002/phar.4612 (opens in new tab) Full text (opens in new tab) Catatonia treatment Ketamine therapy Geriatric psychiatry Schizophrenia management +1

Ketamine Impact on Kidney Health.

Cureus October 1, 2024 Sana Rahman, Samiya Saher, Anurag Raje et al.

Ketamine-induced uropathy (KIU) is a serious consequence of chronic ketamine abuse, presenting with complex renal and urinary symptoms. This study describes a 34-year-old female with a history of chronic ketamine abuse, resulting in stage 3 chronic kidney disease (CKD) and severe urological complications. Despite discontinuing ketamine use five years ago, she remains dependent on ureteral...

DOI: 10.7759/cureus.70804 (opens in new tab) Full text (opens in new tab) Bilateral hydronephrosis Burning micturition Dysuria Flank pain +10

Esketamine mitigates mechanical ventilation-induced lung injury in chronic obstructive pulmonary disease rats via inhibition of the MAPK/NF-κB signaling pathway and reduction of oxidative stress.

International Immunopharmacology September 30, 2024 San-Ying Cai, Ang Liu, Wen-Xi Xie et al. 13 citations

To investigate esketamine's impact on inflammation and oxidative stress in ventilated chronic obstructive pulmonary disease (COPD) rats, examining its regulatory mechanisms. Rats were divided into four groups: control group (Con), COPD model group (M), COPD model with saline treatment group (M+S), and COPD model with esketamine treatment group (M+K), with 12 rats in each group. After two...

DOI: 10.1016/j.intimp.2024.112725 (opens in new tab) Full text (opens in new tab) Esketamine Inflammation Mechanical ventilation Oxidative stress +5